LEAVE Safe With DOACs

NACompletedINTERVENTIONAL
Enrollment

561

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

December 1, 2021

Study Completion Date

September 14, 2022

Conditions
Cardiovascular DiseasesVenous ThromboembolismAtrial FibrillationBleedingStroke
Interventions
OTHER

Clinical Pharmacist Intervention

After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.

Trial Locations (1)

01605

UMass Memorial Medical Center, Worcester

All Listed Sponsors
collaborator

Agency for Healthcare Research and Quality (AHRQ)

FED

lead

University of Massachusetts, Worcester

OTHER

NCT04068727 - LEAVE Safe With DOACs | Biotech Hunter | Biotech Hunter